Therapeutic Drug Monitoring Can Improve Linezolid Dosing Regimens in Current Clinical Practice: A Review of Linezolid Pharmacokinetics and Pharmacodynamics
Authors:
- 1 February 2020
- journal article
- review article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 42 (1) , 83-92
Abstract
Linezolid is an antibiotic used to treat infections caused by drug-resistant gram-positive organisms, including vancomycin-resistantEnterococcus faecium, multi-drug resistantStreptococcus pneumoniae, and methicillin-resistantStaphylococcus aureus. The adverse effects of linezolid can include thrombocytopenia and neuropathy, which are more prevalent with higher exposures and longer treatment durations. Although linezolid is traditionally administered at a standard 600 mg dose every 12 hours, the resulting exposure can vary greatly between patients and can lead to treatment failure or toxicity. The efficacy and toxicity of linezolid are determined by the exposure achieved in the patient; numerous clinical and population pharmacokinetics (popPK) studies have identified threshold measurements for both parameters. Several special populations with an increased need for linezolid dose adjustments have also been identified. Therapeutic Drug Monitoring (TDM) is a clinical strategy that assesses the response of an individual patient and helps adjust the dosing regimen to maximize efficacy while minimizing toxicity. Adaptive feedback control and model-informed precision dosing are additional strategies that use Bayesian algorithms and PK models to predict patient-specific drug exposure. TDM is a very useful tool for patient populations with sparse clinical data or known alterations in pharmacokinetics, including children, patients with renal insufficiency or those receiving renal replacement therapy, and patients taking co-medications known to interact with linezolid. As part of the clinical workflow, clinicians can use TDM with the thresholds summarized from the current literature to improve linezolid dosing for patients and maximize the probability of treatment success.Keywords
This publication has 82 references indexed in Scilit:
- Pharmacokinetics of Intravenous and Oral Linezolid in Adults with Cystic FibrosisAntimicrobial Agents and Chemotherapy, 2011
- Clinical Outcomes of Linezolid vs Vancomycin in Methicillin-Resistant Staphylococcus aureus Ventilator-Associated PneumoniaJournal of Intensive Care Medicine, 2011
- Population Pharmacokinetic and Pharmacodynamic Analysis of Linezolid and a Hematologic Side Effect, Thrombocytopenia, in Japanese PatientsAntimicrobial Agents and Chemotherapy, 2011
- Therapeutic Drug Monitoring of Linezolid: a Retrospective Monocentric AnalysisAntimicrobial Agents and Chemotherapy, 2010
- Limited Sampling Strategies for Therapeutic Drug Monitoring of Linezolid in Patients With Multidrug-Resistant TuberculosisTherapeutic Drug Monitoring, 2010
- Linezolid and Serotonin SyndromeThe Primary Care Companion For CNS Disorders, 2009
- Population Pharmacokinetics of Linezolid in Adults with Pulmonary TuberculosisAntimicrobial Agents and Chemotherapy, 2009
- Pharmacokinetic/Pharmacodynamic Factors Influencing Emergence of Resistance to Linezolid in an In Vitro ModelAntimicrobial Agents and Chemotherapy, 2007
- Clinical Pharmacodynamics of Linezolid in Seriously Ill Patients Treated in a Compassionate Use ProgrammeClinical Pharmacokinetics, 2003
- Oxazolidinones, a new class of synthetic antituberculosis agent in vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosisDiagnostic Microbiology and Infectious Disease, 1991